TNFRSF9 and cancer: Given the prevalence of PD-1+4-1BB+ TILs, targeting them in cancer immunotherapy appears reasonable despite the potential exhaustion [41], especially since it has been demonstrated that 4-1BB can trigger human NK cell proliferation and activation [42] and could restore cytotoxic activity in suppressed NK cells [43].